➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Baxter
McKesson
AstraZeneca
Harvard Business School

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CISATRACURIUM BESYLATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cisatracurium Besylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02508857 Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries Completed Instituto do Cancer do Estado de São Paulo Phase 4 2010-01-01 Magnesium sulfate has been reported to improve postoperative pain, but evidence is still controversial. Some studies demonstrated benefits while others concluded that there is no efficacy. Aim: the aim of the study was to compare the effect of intravenous infusion of magnesium sulfate to ketorolac during laparoscopic gynecologic oncology surgeries. Methods: We designed a double-blind randomized controlled trial that compared intravenous magnesium sulfate to ketorolac and saline solution in postoperative pain, morphine consumption and opioid related side effects.
NCT02588118 Gender and PK-PD of Propofol and Cisatracurium Completed Medical University of Graz N/A 2010-01-01 In recent years it has become clear that gender differences exist both in the pharmacokinetics and the pharmacodynamics of drugs related to the practice of anesthesia. Differences in pharmacokinetics are more straightforward to study than differences in clinical effects. However, isolated pharmacokinetic data are of less value if they are not accompanied by measurements of clinical effects. Males are more sensitive than females to propofol. It may therefore be necessary to decrease the propofol dose by 30-40% in males. Females have 20-30% greater sensitivity to the muscle relaxant effects.
NCT02820025 The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence Recruiting General Hospital of Ningxia Medical University N/A 2015-10-01 The current study is designed to investigate the difference of plasma orexin A levels between doxapram group and controlled group at emergence time from sevoflurane-remifentanil anesthesia who will undergo elective lumbar surgery.
NCT03025295 The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine Recruiting General Hospital of Ningxia Medical University N/A 2016-07-01 The current study is designed to investigate the difference of plasma orexin A levels between Dexmedetomidine group and controlled group at emergence time from total intravenous anesthesia who will undergo elective lumbar surgery.
NCT03337373 The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium Not yet recruiting Mahidol University Phase 4 2017-11-15 Pathophysiological changes influenced by multiple factors in critically ill patients, has a significant impact on pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium. In order to understand better and find an appropriate dosing regimen, the purpose of this study is to investigate the PK and PD of a loading dose cisatracurium in critically ill patients. Cisatracurium, nondepolarizing neuromuscular blocking agents (NMBAs), are commonly used in intensive care units because of a lesser effect on hemodynamic parameters and a reduction in mortality rate in ARDS patients. Loading dose recommended in clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient is 0.1-0.2 mg/kg. Then, maintenance dose of 1-3 mcg/kg/min is followed regarding indications, such as ARDS. However, this recommended loading dose might not be adequate in critically ill patients, the study in this specific population might be needed.
NCT04208594 Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery Recruiting Alexandria University N/A 2019-12-11 50 Patients, aged from 18 to 39 years, ASA physical status I and II, undergoing endoscopic sinus surgery will be enrolled in the study.The patients will be randomly allocated by simple randomization using a computer programme into two groups by closed envelope technique (having 25 patients in each group): GROUP (P): will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK), 10 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 10 mg tablet one hour before the induction of anesthesia. GROUP (I): will receive oral ivabradine (Procoralan® 5mg manufactured by Servier laboratories, France), 5 mg one tablet at 8:00 pm in the evening before the day of the surgery and one 5 mg tablet one hour before the induction of anesthesia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cisatracurium Besylate

Condition Name

Condition Name for Cisatracurium Besylate
Intervention Trials
Anesthesia 2
Gender 1
Propranolol 1
Critical Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cisatracurium Besylate
Intervention Trials
Respiratory Distress Syndrome, Adult 1
Paralysis 1
Critical Illness 1
Acute Lung Injury 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cisatracurium Besylate

Trials by Country

Trials by Country for Cisatracurium Besylate
Location Trials
China 2
Austria 1
Egypt 1
Brazil 1
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cisatracurium Besylate

Clinical Trial Phase

Clinical Trial Phase for Cisatracurium Besylate
Clinical Trial Phase Trials
Phase 4 2
N/A 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cisatracurium Besylate
Clinical Trial Phase Trials
Recruiting 3
Completed 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cisatracurium Besylate

Sponsor Name

Sponsor Name for Cisatracurium Besylate
Sponsor Trials
General Hospital of Ningxia Medical University 2
Alexandria University 1
Mahidol University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cisatracurium Besylate
Sponsor Trials
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Baxter
Moodys
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.